Skip to content
Screener

Sutro Biopharma STRO Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$9.7MMiss by $450.5K
EPS-$6.70Miss by $2.50
Revenue estimate$10.1M
EPS estimate-$4.20

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$13.6M
EPS estimate-$1.66

Financials

Q3 2025

Income statement

See full
Revenue$9.7M+13.8%
Operating income-$48.5M+28.7%
Net income-$56.9M-16.5%
EPS (diluted)-$0.67-13.6%

Balance sheet

See full
Cash & equivalents$65.9M-62.2%
Total debt$17.7M-29.0%
Total equity-$87.3M-178%
Total assets$209.7M-53.6%

Cash flow

See full
Operating cash flow-$38.2M+40.8%
CapEx$47.0K-91.5%
Free cash flow-$38.2M+41.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$73.62M-73.8%
Enterprise value$25.35M-80.7%
P/S0.7×-1.0×

Profitability

See full
Operating margin-175.7%—
Net margin-205.2%—
FCF margin-210.7%—

Returns & leverage

See full
Current ratio2.5×-0.6×

Segments

By product

See full
Ongoing Performance Related To Unsatisfied Performance Obligations$6.0M+16.9%
Materials Supply$2.4M+2,523%
Financing Component On Unearned Revenue$646.0K-49.1%
Research And Development Services$524.0K-58.9%

FAQ

When did Sutro Biopharma report Q3 2025 earnings?
Sutro Biopharma (STRO) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Sutro Biopharma's Q3 2025 revenue and EPS?
Sutro Biopharma reported revenue of $9.7M and eps of $-6.70 for Q3 2025.
Did Sutro Biopharma beat estimates in Q3 2025?
Revenue missed the consensus estimate of $10.1M by $450.5K. EPS missed the consensus estimate of $-4.20 by $2.50.
How did Sutro Biopharma's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.8% from $8.5M a year earlier and eps declined 1035.6% from $-0.59.
Where can I find Sutro Biopharma's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269833) and the 10-Q periodic report (0001193125-25-270036) directly on SEC EDGAR. The filing index links above go to sec.gov.